T Cell Receptor Therapies Articles & Analysis
27 articles found
By administering recombinant chemokines, scientists can redirect immune cells to the tumor microenvironment, potentially enhancing the efficacy of checkpoint inhibitors or CAR-T cell therapies. For instance, CXCL10 has shown promise in preclinical models by enhancing T-cell infiltration into ...
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering ...
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. This initiative marks a significant advancement in the quest for more effective cancer therapies, focusing on enhancing precision and adaptability in treatment ...
Among the various forms of immunotherapy, CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) has shown promise, particularly in treating acute lymphoblastic leukemia (ALL), especially in children and young adults. This therapy involves genetically ...
These technologies allow scientists to cut, insert, or modify specific DNA sequences, enabling the customization of T cells to recognize and attack disease-specific antigens. Applications in Cancer Therapy One of the most promising applications of gene editing in primary T cells is in cancer ...
The emergence of chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of certain cancers, providing a promising targeted approach to eliminate cancer cells. ...
What is CAR T-cell therapy? Car-t cell therapy involves genetically engineering T cells isolated from patients or allogeneic donors to express chimeric antigen receptors (CAR) that specifically recognize and kill tumor cells. ...
This heightened expression of CD19 makes it a valuable target for treating these diseases. CAR-T cell therapy, an immunotherapy, has demonstrated efficacy in treating B-cell lymphoma by genetically modifying the patient's T cells to carry CD19-specific receptors. ...
Low Endotoxin Cytokines Matters Organoid culture, CAR-T cell therapy, stem cell therapy, and other topics have become broadly discussed among biomedical researchers. ...
One such mechanism are the so-called “immune checkpoints”: these are molecules found on the surface of T cells. When a cell binds both the T-cell receptor (the receptor specific for a given antigen, that gives a T cell its ...
So far, anti-mesothelin antibody-drug conjugates have been successfully used to treat mesothelin-expressing solid tumors, including ovarian cancer, pancreatic cancer, and malignant mesothelioma; and mesothelin targets chimeric antigen receptor (CAR) T cell therapy also showed significant antitumor effects. Therefore, targeted ...
Cytokines-mediated signaling is a primary way of immune system communication. The common gamma-chain family of cytokines is a set of six cytokines that signal through the common cytokine γ chain receptor (γc/CD132/IL2RG). These cytokines include IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Besides the IL-2RG receptor subunit, the γc family cytokine receptors include IL-2RB ...
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. ...
The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen receptor (CAR) is a synthetic molecule that specifically commands T cells of the immune system to recognize and adhere to a target or antigen. ...
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has ...
Gene editing technology, represented by CRISPR/Cas9, has greatly accelerated the development of gene therapy, bringing hope to many genetic diseases that otherwise had no cure. In June 2021, Intellia Therapeutics' NTLA-2001, a CRISPR gene editing therapy for the treatment of transthyretin amyloidosis (ATTR) invented by Nobel Laureate Jennifer Doudna, was proven to be safe and effective in a ...
More recently, bispecific antibodies and chimeric antigen receptor T (CAR-T) cells, including those for anti-TACA, have been evaluated in the clinic and have made impressive progress. ...
Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. ...
Heart failure, liver disease, and kidney failure are just a few of the major conditions that can result from cardiac fibrosis. The FDA approved CAR-T cell therapy, also known as chimeric antigen receptor T-cell therapy, as the first CAR-T cell ...
This also marks the arrival of the era of cell therapy. Today, CAR-T has become one of the most important new developments in cancer immunotherapy, and many breakthroughs have been made in hematological tumors, but CAR-T therapy is usually limited by T cell failure. ...